 
					ISSUE 5 of 6 - In Vitro Diagnostics Business Outlook: Focus on Continuous Glucose Monitoring (CGM)
Description
						The in vitro diagnostics (IVD) sector stands as a cornerstone of modern healthcare, empowering clinicians with the tools to detect diseases, monitor health conditions, and guide precise treatment decisions. 
As healthcare evolves, the IVD market is poised for transformative growth. With the rising prevalence of chronic conditions such as diabetes and cardiovascular diseases, as well as ongoing threats from infectious diseases like COVID-19 and emerging variants, the demand for innovative diagnostic solutions has never been greater.
In Vitro Diagnostics Business Outlook is a bimonthly publication, delivering six issues annually, each dedicated to a different segment of the IVD industry. It provides exclusive insights and data, including:
							
						
					
				As healthcare evolves, the IVD market is poised for transformative growth. With the rising prevalence of chronic conditions such as diabetes and cardiovascular diseases, as well as ongoing threats from infectious diseases like COVID-19 and emerging variants, the demand for innovative diagnostic solutions has never been greater.
In Vitro Diagnostics Business Outlook is a bimonthly publication, delivering six issues annually, each dedicated to a different segment of the IVD industry. It provides exclusive insights and data, including:
- Market Data and Forecasts: Detailed growth rates, market size, and market share to identify new opportunities.
- Comprehensive Market View: Coverage of test categories and company profiles.
- M&A Activities: Updates on mergers, acquisitions, partnerships, and collaborations.
- Industry & Region Watch: Tailored strategies based on regional and industry-specific trends.
- News Analysis: In-depth reporting on significant news and events, including exclusive information not readily available elsewhere.
Table of Contents
										49 Pages
									
							- MARKET ANALYSIS: CONTINUOUS GLUCOSE MONITORING
- OVERVIEW OF CONTINUOUS GLUCOSE MONITORING
- MARKET OUTLOOK: CONTINUOUS GLUCOSE MONITORING
- OVERVIEW OF CONTINUOUS GLUCOSE MONITORING
- Table: Glucose Testing Market, Sales by Broad Category, 2025 and 2030 ($ million) [Glucose Continuous, Glucose OTC, Glucose Professional]
- Figure: Glucose Testing Market, Continuous Glucose Monitor Distribution of Total Sales, 2025 and 2030 [Glucose Continuous and Remaining Glucose Testing Market]
- Figure: Glucose Testing Market, Continuous Glucose Monitor, Estimated Distribution of Total Sales by Modality [rtCGM, isCGM, implantable CGM], 2025 (%)
- REGIONAL MARKET
- Figure: Global Continuous Glucose Testing Market, Estimated Market Value by Region, 2025 ($ million) [Europe, Japan, United States, RoW]
- COMPANY BRIEFS
- Abbott Diagnostics
- Medtronic
- Dexcom
- Senseonics
- EXECUTIVE NEWS BRIEFING
- RAPIDEMIC SECURES €2.3 MILLION GRANT
- STRATIFAI SECURES €12.5 MILLION FOR PRECISION ONCOLOGY
- PREDICTA BIOSCIENCES RAISES $23.4 MILLION IN SERIES A FUNDING
- PREDICTA BIOSCIENCES WELCOMES NEW CEO
- OWLSTONE MEDICAL SCORES $49.1 MILLION
- FINANCIAL HIGHLIGHTS: FULGENT GENETICS, THERMO FISHER SCIENTIFIC
- FULGENT GENETICS POSTS STRONG PERFORMANCE IN CORE REVENUE
- Figure: Fulgent Genetics’ Financial Results by Q1 2024 Through Q2 2025 ($ million)
- Figure: Fulgent Genetics Distribution of Revenues by Payor, H1 2025
- Figure: Fulgent Genetics Revenue Performance by Geographic Region, H1 2025
- THERMO FISHER MAINTAINS STEADY PERFORMANCE IN H1 2025
- Table: Thermo Fisher Scientific Sales by Division, 6M 2024 and 6M 2025 ($ million)
- Figure: Thermo Fisher Scientific, Sales by Division, 6M 2024 and 6M 2025 ($ million)
- Table: Thermo Fisher Scientific 2025 Highlights by Quarter, Q1 2025 vs. Q2 2025
- DIAGNOSTIC MARKET MERGERS, ACQUISITIONS, AND PARTNERSHIP DEALS
- PARTNERSHIPS AND COLLABORATIONS
- Mergers and Acquisitions
- Table: Recent Diagnostic Market Mergers, Acquisitions, and Partnership Deals, Dec. 2024-Oct. 2025
- INDUSTRY WATCH
- INDUSTRY WATCH COVID-19/FLU UPDATE
- REGION WATCH
- BELGIUM
- Figure: Belgium: Overall Share of Health Spending (Government/Compulsory Schemes, Out-of-Pocket [OOP], Voluntary Health Insurance [VHI]), 2023
- Figure: Belgium: Market Distribution of Broad IVD Segments, 2025 (%)
- BROAD-BASED COMPANY ANNOUNCEMENTS
- GUARDANT HEALTH SECURES FDA NOD FOR CDX
- CLEARNOTE HEALTH RECEIVES UKCA APPROVAL FOR TWO EARLY DETECTION CANCER TESTS
- XPEDITE DX LAUNCHES ONE-STEP VIRAL DNA/RNA EXTRACTION KIT
- NEUROKAIRE LAUNCHES UNIQUE TEST FOR MDD
- MIRXES GAINS NMPA APPROVAL
- CND LIFE SCIENCES SCORES FDA BREAKTHROUGH DEVICE DESIGNATION
- HOLOGIC GAINS FDA AND CE MARK FOR MOLECULAR TESTS
- J&J INTENDS TO SPIN OFF ORTHOPEDIC BUSINESS
- ROCHE RECEIVES GO-AHEAD FROM FDA
Search Inside Report
Pricing
Currency Rates 
		Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
		
	


